Business Development

Neuromodulation Market – Poised for Rapid Growth

Neuromodulation refers to both the electrical and chemical stimulation of the nervous system to alter some neurological or neurally mediated function. In 2006, the U.S. neuromodulation market was valued at $1.5 billion and expected to double to $3 billion by 2010. Many industry observers believe that this substantial growth rate is firmly supported by the global prevalence of various neuromuscular diseases, aging demographics, changing social attitudes and the individual’s desire to restore and maintain a higher quality of life. As a result, many companies are actively engaged in the development of neuromodulation technologies to treat a wide array of physical dysfunctions to include:

  • Spinal Cord Stimulation
    • Angina pain management
    • Peripheral vascular disease pain
  • Deep Brain Stimulation
    • Depression/OCD
    • Stroke
    • Epilepsy
    • Brain injury
  • Vagus Nerve Stimulation
    • Alzheimer’s disease
    • Anxiety disorders
    • Severe refractory headache
    • Sleep apnea
  • Sacral Nerve Stimulation
    • Pelvic pain
    • Urinary incontinence
    • Sexual dysfunction
  • Gastric Stimulation
    • Obesity

Strong Patent Portfolio

Neurostream’s core objective is to improve the quality of life of people suffering from gait disorders. A key element to realizing this goal is, when appropriate, to acquire technologies and businesses that provide key strategic advantages in the pursuit of our overarching corporate objectives. Today, Neurostream holds 20 issued and 24 pending patents worldwide in the neurostimulation and associated fields, including a number of valuable and relevant technology platforms that have been reduced to practice. These include:

  • Neurocuff™ – an “intelligent” electrode design providing selective nerve sensing and stimulation;
  • Neurosensing – a combination of advanced hardware and software that amplifies, filters and detects specific impulses or events from the human nervous system;
  • Neurolink™ ENG signal processing – a proprietary technology that enables nerve event identification from a pool of signals and noise within the human body;
  • Bionized™ CLS – a “closed-loop system” that allows for two-way communication and real-time interaction with the nervous system.

Seeking Partners in the Neurostimulation Field

Neurostream continues to focus on the research, development and commercialization of implantable neurostimulation devices to treat certain movement disorders. However, we also recognize that our current technology portfolio may have broader potential in other clinical applications outside of gait disorders. Therefore, our business development team is currently pursuing partnerships with inventors and companies to help accelerate their development processes by providing access to our proprietary neuromodulation platforms. Our team of technical and business professionals are prepared to assist interested parties in a variety of device development and product commercialization activities including concept evaluation, preclinical study, market analysis and product introduction strategies.

If you are interested and would like to have a representative from Neurostream contact you about potential business development opportunities, please fill out the contact form and someone will contact you shortly.